Vitae Pharmaceuticals (VTAE) Tops Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. COIN
5. PINS
6. FSLR
7. SYK
8. GILD
9. SBUX
10. SNDK

Go back to Vitae Pharmaceuticals (VTAE) Tops Q1 EPS by 7c

Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results

May 10, 2016 4:01 PM EDT

Proof-of-concept data for VTP-38543 expected in the second half of 2016

Conference call scheduled for 4:30 p.m. EDT today

FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended March 31, 2016.

Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, The highlight of the first quarter was the positive top-line results from Vitaes Phase 2a proof-of-concept clinical trial of VTP-43742, our wholly owned, first-in-class RORt inhibitor, in... More